Follow-The-Filings

Security · featured owners

BSX Boston Scientific Corp.

Health Care COM Equity as of 2026 Q2 among managers we track

  • 9 Owners
  • #135
  • Max 2.2%
  • Master 0.04%
  • $759M
  • 3 new 3 add 3 reduce 2 exits

BSX (Boston Scientific Corp.) is held in 9 featured 13F books as of 2026 Q2. Lee Ainslie - Maverick Capital is the largest tracked holder by portfolio weight (2.2%). Figures are as-filed 13F, not free float.

Who owns this now

Largest portfolio weights among featured holders · max 2.2% (Lee Ainslie - Maverick Capital) · not free-float ownership

  1. Lee Ainslie add 2.2%
  2. Farallon Capital Management add 2.1%
  3. David Witzke add 0.55%
  4. Senator Investment Group new 0.47%
  5. Sarah Ketterer new 0.33%
  6. Glenview Capital Management new 0.09%

holders

sorted by value · long equity only · current book 2026 Q2 · open a manager for their book

history
Farallon Capital Management 2026 Q2 2.1% Add +40.8% 10,521,184 $449M history
Lee Ainslie - Maverick Capital 2026 Q2 2.2% Add +41.5% 5,937,553 $253M history
Sarah Ketterer - Causeway Capital Management 2026 Q2 0.33% New 0.33% 720,339 $31M history
Senator Investment Group 2026 Q2 0.47% New 0.47% 300,000 $13M history
Glenview Capital Management 2026 Q2 0.09% New 0.09% 113,096 $5M history
Dodge & Cox 2026 Q2 <0.01% Reduce −1.6% 87,485 $4M history
David Witzke - Avidity Partners Management 2026 Q2 0.55% Add +33.3% 80,000 $3M history
Mairs & Power 2026 Q2 <0.01% Reduce −2.6% 9,914 $423K history
Polen Capital Management 2026 Q2 <0.01% Reduce −99.2% 4,750 $203K history
Stephen Mandel - Lone Pine Capital exited 2026 Q2 last 2026 Q1 0.05% Exit −0.05% 104,655 $7M history
Davidson Kempner Capital Management exited 2026 Q2 last 2026 Q1 0.05% Exit −0.05% 63,250 $4M history

9 current · 2 exited last period · options excluded

SEC filings

Recent issuer filings from EDGAR · 13 shown · open Filing / Doc on SEC.gov

Filed Form Detail Links
8-K 1.05 Filing Doc
8-K 8.01 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 2.05 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 5.03,5.07,9.01 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
424B3 Filing Doc
8-K 8.01,9.01 Filing Doc
DEFA14A Filing Doc

Insider forms

Form 3 / 4 / 5 from EDGAR · 13 rows shown

Filed Form Detail Links
4 Period Sep 2, 2026 Filing Doc
4 Period Aug 25, 2026 Filing Doc
4 Period Aug 11, 2026 Filing Doc
4 Period Aug 10, 2026 Filing Doc
4 Period Aug 5, 2026 Filing Doc
4 Period Aug 3, 2026 · 2 forms Filing Doc
4 Period Jul 31, 2026 · 2 forms Filing Doc
4 Period Jul 1, 2026 Filing Doc
4 Period May 28, 2026 Filing Doc
4 Period May 19, 2026 Filing Doc
4 Period May 20, 2026 · 2 forms Filing Doc
4 Period May 7, 2026 · 9 forms Filing Doc
4 Period May 2, 2026 · 2 forms Filing Doc

Updated 7 days ago Source: SEC EDGAR submissions All on EDGAR

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $14.24B $16.75B $20.07B
Gross profit $9.9B $11.49B $13.85B
Gross margin * 69.5% 68.6% 69.0%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $6.51B $6.92B $8.79B
Total non-current assets * $28.62B $32.48B $34.88B
Total assets $35.14B $39.4B $43.67B
Total current liabilities $4.93B $6.4B $5.44B
Total equity $19.28B $21.77B $24.23B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $2.5B $3.44B $4.53B
Cash from investing -$2.57B -$5.69B -$2.64B
Cash from financing $0.005B $1.81B -$0.395B
Net change in cash -$0.07B -$0.45B $1.54B

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders